The Role of Inflammation in Bladder Cancer

被引:86
作者
Gakis, Georgios [1 ]
机构
[1] Univ Tubingen, Dept Urol, Univ Tubingen Hosp, D-72076 Tubingen, Germany
来源
INFLAMMATION AND CANCER | 2014年 / 816卷
关键词
C-REACTIVE PROTEIN; INVASIVE UROTHELIAL CARCINOMA; TRANSFORMATION IN-VITRO; BCG IMMUNOTHERAPY; PROGNOSTIC VALUE; EAU GUIDELINES; CELL-LINE; SURVIVAL; METASTASIS; EXPRESSION;
D O I
10.1007/978-3-0348-0837-8_8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this book chapter is to present the latest basic research developments on the role of inflammation in bladder cancer and provide insights into their future clinical significance in preventing bladder carcinogenesis and progression. Bladder cancer is a highly immunogenic malignancy. Urothelial cancer cells aim to manipulate the immune system by inhibiting its cytotoxic function while stimulating the secretion of growth promoting factors. Cytokine-induced imbalances in the distribution and differentiation of tumor-infiltrating cytotoxic cells can boost bladder cancer cell proliferation. Tumor-induced release of excessive amount of cytokines causes an "inflammatory storm" which drives metastasis formation via degradation of extracellular matrix proteins. Tumor-related selective cyclooxygenase-2 (COX-2) upregulation suppresses the cell-mediated immune response via aberrant prostaglandin metabolism resulting in failure of differentiation of myeloid cell progenitors into mature antigen-presenting cells. T cells are capable of increasing the oxidative stress on bladder cancer cells via induction of COX-2 and STEAP expression. Some evidence also suggests that COX-2 activation may be also involved in inflammation-mediated cancer stem cell proliferation. Antibodies against the VEGF-co-receptor neuropilin decrease the angiogenetic potential of bladder cancer cells. Inflammation-based predictive bladder cancer models have demonstrated to accurately predict response to treatment both in the curative and palliative setting. While randomized trials do not support a clinical benefit for the use of anti-inflammatory drugs (i.e., celecoxib, atorvastatin) in preventing recurrence of low-grade bladder cancer, further investigations are warranted in the setting of high-grade tumors since the immune response to cancer stimuli is most probably more pronounced in advanced stages.
引用
收藏
页码:183 / 196
页数:14
相关论文
共 47 条
[1]   Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysis [J].
Abdollah, Firas ;
Gandaglia, Giorgio ;
Thuret, Rodolphe ;
Schmitges, Jan ;
Tian, Zhe ;
Jeldres, Claudio ;
Passoni, Niccolo Maria ;
Briganti, Alberto ;
Shariat, Shahrokh F. ;
Perrotte, Paul ;
Montorsi, Francesco ;
Karakiewicz, Pierre I. ;
Sun, Maxine .
CANCER EPIDEMIOLOGY, 2013, 37 (03) :219-225
[2]   Prognostic Value of Tumor-associated Macrophages Count in Human Non-muscle-invasive Bladder Cancer Treated by BCG Immunotherapy [J].
Ajili, Faouzia ;
Kourda, Nadia ;
Darouiche, Amine ;
Chebil, Mouhamed ;
Boubaker, Samir .
ULTRASTRUCTURAL PATHOLOGY, 2013, 37 (01) :56-61
[3]   Six-Transmembrane Epithelial Antigen of the Prostate as an Immunotherapeutic Target for Renal Cell and Bladder Cancer [J].
Azumi, Makoto ;
Kobayashi, Hiroya ;
Aoki, Naoko ;
Sato, Keisuke ;
Kimura, Shoji ;
Kakizaki, Hidehiro ;
Tateno, Masatoshi .
JOURNAL OF UROLOGY, 2010, 183 (05) :2036-2044
[4]   EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update [J].
Babjuk, Marko ;
Oosterlinck, Willem ;
Sylvester, Richard ;
Kaasinen, Eero ;
Boehle, Andreas ;
Palou-Redorta, Juan ;
Roupret, Morgan .
EUROPEAN UROLOGY, 2011, 59 (06) :997-1008
[5]   Inflammation and cancer: back to Virchow? [J].
Balkwill, F ;
Mantovani, A .
LANCET, 2001, 357 (9255) :539-545
[6]   Expression of cyclooxygenase-1 and-2 in urinary bladder carcinoma in vivo and in vitro and prostaglandin E2 synthesis in cultured bladder cancer cells [J].
Boström, PJ ;
Aaltonen, V ;
Söderstrom, KO ;
Uotila, P ;
Laato, M .
PATHOLOGY, 2001, 33 (04) :469-474
[7]   Interferon-α inhibits cyclooxygenase-1 and stimulates cyclooxygenase-2 expression in bladder cancer cells in vitro [J].
Boström, PJ ;
Uotila, P ;
Rajala, P ;
Nurmi, M ;
Huhtaniemi, I ;
Laato, M .
UROLOGICAL RESEARCH, 2001, 29 (01) :20-24
[8]   Adenosine A2B Receptor Blockade Slows Growth of Bladder and Breast Tumors [J].
Cekic, Caglar ;
Sag, Duygu ;
Li, Yuesheng ;
Theodorescu, Dan ;
Strieter, Robert M. ;
Linden, Joel .
JOURNAL OF IMMUNOLOGY, 2012, 188 (01) :198-205
[9]   Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma [J].
Chi, L. J. ;
Lu, H. T. ;
Li, G. L. ;
Wang, X. M. ;
Su, Y. ;
Xu, W. H. ;
Shen, B. Z. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2010, 161 (03) :480-489
[10]   Pro-inflammatory type-1 and anti-inflammatory type-2 macrophages differentially modulate cell survival and invasion of human bladder carcinoma T24 cells [J].
Dufresne, Mathieu ;
Dumas, Genevieve ;
Asselin, Eric ;
Carrier, Christian ;
Pouliot, Marc ;
Reyes-Moreno, Carlos .
MOLECULAR IMMUNOLOGY, 2011, 48 (12-13) :1556-1567